What is Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s (688621.SS) StockRank?

MoatMap's StockRank for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) is 26/100, with a Sell signal. This is a composite score combining Quality (59), Value (25), and Momentum (34) factor ranks across MoatMap's 20,000+ stock universe.

Does Beijing Sun-Novo Pharmaceutical Research Co., Ltd. have an economic moat?

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) has a Quality factor score of 59/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. in?

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688621.SS

SELLREMOVE

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. · Healthcare · China · $894M · Avg Vol: $15M/d

StockRank

P/E (TTM)

29.7x

ROE

17.5%

D/E

0.5x

Dividend %

0.4%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Beijing Sun-Novo Pharmaceutical is a CRO/CDMO focused on drug discovery and clinical trials. While it operates in a structurally growing sector, it lacks the global scale, regulatory validation, and high-margin biologics capabilities of top-tier CDMO gatekeepers.

COMPANY DESCRIPTION

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is a leading contract research organization (CRO) providing end-to-end pharmaceutical R&D services, from drug discovery and preclinical evaluation to clinical trials and registration. The company specializes in both chemical drugs and biologics, offering a highly integrated service model that accelerates drug development timelines for biotech clients. Its competitive advantage lies in its comprehensive regulatory expertise, high-quality laboratory infrastructure, and a strong track record of successful IND and NDA filings.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	100M	138M	159M	181M	21.8%
EPS	0.21	0.24	0.23	0.27	9.9%
Shares	112M	112M	112M	112M	0.0%
Debt	38M	66M	67M	91M	33.6%
Equity	133M	154M	163M	180M	10.7%
Op CF	15M	14M	5M	14M	-3.6%
Inv CF	-2M	-13M	-6M	-30M	—
Fin CF	4M	11M	-19M	3M	—

PRICE (1M)-9.6%

SMA 50SMA 200

$7.63

RSI (14)

39.2

52W High

$12.78

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

17.1%88.8

ROE

17.5%86.6

GP/Assets

28.6%63.1

Op. Margin

7.6%60.6

FCF/Assets

-9.0%29.2

Piotroski

—55.7

Int. Cover

13.7x69.0

D/E Ratio

0.48x32.4

Current Ratio

1.79x32.9

Value

P/E (TTM)

29.7x36.9

EV/EBITDA

26.3x13.5

P/FCF

—N/A

P/B

4.6x26.5

P/S

5.0x41.4

Div Yield

0.4%10.1

Momentum

52W High %

60%39.8

RS 6M

-30%41.1

SMA 50/200

0.90x34.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-30%18.4

FUNDAMENTALS

Market Cap

$894M

P/E (Forward)

—

Gross Margin

54.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688621.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688621.SS	Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(you)	$894M	26	SELL
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.	$994M	26	SELL
300702.SZ	Zhejiang Tianyu Pharmaceutical Co., Ltd.	$989M	26	SELL
002038.SZ	Beijing SL Pharmaceutical Co., Ltd.	$893M	28	SELL
002907.SZ	Chongqing Pharscin Pharmaceutical Co., Ltd.	$765M	26	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
600422.SS	KPC Pharmaceuticals,Inc.	$999M	24	SELL
688176.SS	Jiangsu Yahong Meditech Co., Ltd.	$961M	30	SELL
600252.SS	Guangxi Wuzhou Zhongheng Group Co., Ltd	$1.0B	29	SELL
300363.SZ	Porton Pharma Solutions Ltd.	$1.2B	26	SELL

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) — Stock Score Summary

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) has a MoatMap StockRank of 26/100 based on Quality (59/100), Value (25/100), and Momentum (34/100) factor scores. The current signal is SELL. Beijing Sun-Novo Pharmaceutical is a CRO/CDMO focused on drug discovery and clinical trials. While it operates in a structurally growing sector, it lacks the global scale, regulatory validation, and high-margin biologics capabilities of top-tier CDMO gatekeepers.

Key Financial Metrics

Price	$7.63
Market Cap	$894M
P/E (TTM)	29.75
Price/Book	4.59
Return on Equity	17.5%
Return on Invested Capital	17.1%
Debt/Equity	48.01
Gross Margin	54.8%
Operating Margin	7.6%
Revenue Growth	-14.6%
Dividend Yield	0.4%
Free Cash Flow	$-4M

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Beijing Sun-Novo Pharmaceutical Research Co., Ltd.’s (688621.SS) StockRank?: MoatMap’s StockRank for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) is 26/100, with a Sell signal. It is a composite of Quality (59), Value (25), and Momentum (34) factor ranks across MoatMap’s 20,000+ stock universe.
Does Beijing Sun-Novo Pharmaceutical Research Co., Ltd. have an economic moat?: Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) has a Quality factor score of 59/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Beijing Sun-Novo Pharmaceutical Research Co., Ltd. in?: Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).